Loading
Serina Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Jul 2026.
Serina Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Serina Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 29 filings were filed, from 4 insiders.
Only purchases show up on the open market, 1 purchase in all worth €1,774, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €1,774, the purchase published on 9 July 2026 by Brannan Stephen K. is the largest of the period (0.0036% of market cap). The buyers include 1 senior executive.
Compared with its exchange (5,458 companies, median 22 filings), a count of 29 filings is above the norm. The full history, which starts in 2021, counts 18 purchases against no sales.
The last purchase on record was published on 9 July 2026, which is 101 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
71
Thresholds
n/a
Buy Volume
€423,823
18 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGregory Bailey1 buy
Stephen K. Brannan1 buy
Since the insiders bought
- -19.6%Entry US$2.14 · Close 16 Oct 2026 US$1.72
- -55.8%Entry US$6.00 · Close at T+365 US$2.65
- -22.1%Entry US$6.06 · Close at T+365 US$4.72
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.72
Analyst consensus
2 analysts1.00/5
US$8.00Target US$9.50(+452%)US$11.00
Income statement
EBITDA-US$18.9M
Net income-US$19.2M0.0% margin
Valuation
PER (forward)-2.2x
P/Book2.3x
Beta0.16
Balance sheet & cash
Market capUS$43.7M
Total debtUS$3.1M
Free Cash Flow-US$18M
Debt / Equity20%
Profitability & ownership
ROE-207.9%
ROA-92.3%
% insiders50.8%
% institutions5.5%
Last declaration on 9 July 2026
Declarations71 total
1,000 shares@ US$2.030.0036% mcap100.0% of flowCommon StockSEC:0001777631-26-000007:0
Canonical exit: 5 Oct 2026 (T+90)
1,770,805 sharesCommon StockSEC:0001329505-26-000007:0
6,666,667 sharesCommon StockSEC:0001329505-26-000007:1
59,667 shares@ US$1.940.18% mcap23.2% of flowCommon StockSEC:0001329505-26-000002:0
7,553 shares@ US$1.94100.0% of flowCommon StockSEC:0001413350-26-000002:0
6,500 shares@ US$0.063.3% of flowCommon StockSEC:0001301120-26-000018:0
39,000 shares@ US$0.0620.1% of flowCommon StockSEC:0001301120-26-000016:0
6,500 shares@ US$0.060.0006% mcap3.2% of flowCommon StockSEC:0001301120-26-000012:0
6,500 shares@ US$0.060.0006% mcap3.2% of flowCommon StockSEC:0001301120-26-000010:0
2,500 shares@ US$0.061.3% of flowCommon StockSEC:0001301120-26-000008:0
2,000 shares@ US$0.061.0% of flowCommon StockSEC:0001301120-26-000006:0
5,416 shares@ US$0.060.0005% mcap2.7% of flowCommon StockSEC:0001301120-26-000004:0
13,000 shares@ US$0.060.0012% mcap6.6% of flowCommon StockSEC:0001301120-26-000002:0
4,100 shares@ US$0.062.1% of flowCommon StockSEC:0001301120-25-000039:0
5,673 shares@ US$0.060.0005% mcap2.9% of flowCommon StockSEC:0001301120-25-000037:0
3,227 shares@ US$0.061.6% of flowCommon StockSEC:0001301120-25-000035:0
1,700 shares@ US$0.060.0002% mcap0.9% of flowCommon StockSEC:0001301120-25-000033:0
3,555 shares@ US$0.060.0003% mcap1.8% of flowCommon StockSEC:0001301120-25-000030:0
600 shares@ US$0.060.0001% mcap0.3% of flowCommon StockSEC:0001301120-25-000027:0
1,500 shares@ US$0.060.0001% mcap0.8% of flowCommon StockSEC:0001301120-25-000025:0
5,965 shares@ US$0.063.1% of flowCommon StockSEC:0001301120-25-000023:0
535 shares@ US$0.060.3% of flowCommon StockSEC:0001628280-25-054059:0
6,500 shares@ US$0.063.3% of flowCommon StockSEC:0001301120-25-000021:0
6,500 shares@ US$0.063.3% of flowCommon StockSEC:0001301120-25-000019:0
3,398 shares@ US$0.061.7% of flowCommon StockSEC:0001301120-25-000017:0
25 of 71 declarations
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company listed on the NYSE American market (NYSE/NASDAQ ecosystem, United States) under the ticker SER. For French-, Belgian- and Swiss-based investors, Serina is best viewed as an early-stage biotech whose equity story is primarily driven by clinical milestones, regulatory execution, and financing events rather than by recurring commercial revenue. The company was founded in 2006 and is headquartered in Huntsville, Alabama, United States. Its core strategy is built around a proprietary drug-optimization engine, the POZ Platform™, designed to improve the pharmacokinetic profile, tolerability, and delivery characteristics of known therapies and other modalities.
Serina’s business is centered on developing product candidates for neurological diseases and potentially other indications. Its lead asset is SER-252, a POZylated version of apomorphine being advanced for advanced Parkinson’s disease. The company is positioning SER-252 as a differentiated therapy intended to provide more stable exposure to the active ingredient, with subcutaneous weekly or twice-weekly dosing designed to improve symptom control and patient convenience. Beyond Parkinson’s disease, Serina describes the POZ Platform as potentially applicable to small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs), which gives the company a broader platform narrative than a single-asset biotech.
Read moreShow less
From a competitive standpoint, Serina is not a commercial pharmaceutical company competing on sales scale; it is a specialty biotech competing on technology differentiation, intellectual property, and clinical proof-of-concept. The investment case is therefore asymmetric: if the platform can meaningfully improve established molecules, it could create value across multiple programs, but if the lead clinical program disappoints, downside risk is substantial. The company’s current market position reflects that profile: pre-commercial, platform-driven, and highly dependent on development execution.
Recent news flow has been material. In January 2026, the FDA cleared the Investigational New Drug application for SER-252. In February 2026, Serina announced first patient enrollment in its Phase 1b registrational study in advanced Parkinson’s disease. In March and April 2026, the company closed a private placement that could provide up to $30 million in gross proceeds, strengthening the balance sheet for ongoing development. In its first-quarter 2026 update, Serina said the Phase 1b study is underway and that cohort enrollment remains on track, while it also highlighted continued financing activity and clinical progress. The company also reported that NYSE American accepted its continued-listing compliance plan. Overall, Serina remains a small-cap clinical biotech whose valuation is likely to be dominated by SER-252 data, regulatory progress, and capital-market access over the next several quarters.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
